ZNTL Projected Dividend Yield
Zentalis Pharmaceuticals Inc ( NASDAQ : ZNTL )Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. Co. is focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. Co.'s lead product candidate includes azenosertib (ZN-c3), which is a WEE1 inhibitor for advanced solid tumors and hematological malignancies. Co. is also developing a BCL-2 inhibitor, ZN-d5, for hematological malignancies and related disorders. ZN-d5 is being evaluated in combination with azenosertib in a Phase I/II dose escalation clinical trial in patients with R/R acute myeloid leukemia (AML) (ZN-d5-004C). 20 YEAR PERFORMANCE RESULTS |
ZNTL Dividend History Detail ZNTL Dividend News ZNTL Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |